PT  - JOURNAL ARTICLE
AU  - Zaffiri, L.
AU  - Long, A.
AU  - Neely, M.L.
AU  - Cherikh, W.
AU  - Chambers, D.C.
AU  - Snyder, L. D.
TI  - Incidence and outcomes of post-transplant lymphoproliferative disorders in lung transplant patients: analysis of ISHLT Registry
AID  - 10.1101/2020.01.27.20019042
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.01.27.20019042
4099  - http://medrxiv.org/content/early/2020/01/29/2020.01.27.20019042.short
4100  - http://medrxiv.org/content/early/2020/01/29/2020.01.27.20019042.full
AB  - Background Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complication following lung transplant. We aimed to study the incidence of and risk factors for PTLD in adult lung transplant recipients.Methods The International Society of Heart and Lung Transplant (ISHLT) Registry was used to identify adult, first-time, single and bilateral lung transplant recipients with at least one year follow-up and from centers reporting PTLD between January 2006 and June 2015. Kaplan Meier method was used to describe timing and distribution of PTLD. Univariable and multivariable Cox proportional hazards regression models were used to examine the clinical characteristics associated with PTLD.Results Of the 19,309 lung transplant recipients in the analysis cohort, we identified 454 cases of PTLD. Cumulative incidence of PTLD was 1.1% (95% CI = 1.0%, 1.3%) at 1 year and 4.1% (95% CI= 3.6%, 4.6%) at 10-years. We observed that 47.4% of all PTLD cases occurred within the first year following lung transplantation. In the multivariable model, independent risk factors for PTLD included age, EBV mismatch and native lung diseases. The risk of PTLD during the first year after transplant increased with increasing age in patients between 45 to 62 years at time of transplantation; the inverse was true for ages less than 45 year or greater than 62 years. Finally, receiving a donor organ with human leukocyte antigen (HLA) types A1 and A24 was associated with an increased risk of PTLD while the recipient HLA type DR11 was associated with a decreased risk.Conclusions Our study indicates that PTLD is a relatively rare complication among adult lung transplant recipients. We identified clinical characteristics that are associated with increased risk of PTLD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the International Heart and Lung Transplant Registry through the Transplant Registry Early Career AwardAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.